Abstract: Non-invasive methods permitting accurate detection of innate immune dysfunction are critical to enhance the understanding, diagnosis, and treatment of inflammatory disorders. Identifying specific biomarkers of innate immune cells and their functional phenotypes, paired with subsequent PET tracer development, is thus an area of great interest with important implications for a broad range of diseases. However, existing targets lack cell specificity and/or fail to provide functionally relevant information regarding immune cell status. To overcome these limitations, a PET tracer was developed targeting TREM1 a highly specific biomarker of pro-inflammatory myeloid-driven immune responses.

Abstract: This invention relates to molecular imaging agents comprising an S78C mutant synaptotagmin I C2A domain. These agents may be useful in detecting or assessing cell death in vitro and in vivo, for example in tumors following cancer treatment.

Abstract: This invention relates to molecular imaging agents comprising an S78C mutant synaptotagmin I C2A domain. These agents may be useful in detecting or assessing cell death in vitro and in vivo, for example in tumours following cancer treatment.